IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.